Bionano Genomics (BNGO) Net Cash Flow (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Net Cash Flow data on file, last reported at $414000.0 in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 106.97% year-over-year to $414000.0; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (up 110.72% YoY), and the FY2025 full-year result was -$5.0 million, up 42.88% from the prior year.
• Net Cash Flow slipped to $414000.0 in Q1 2026, from $1.5 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $19.7 million in Q3 2023 to a low of -$22.8 million in Q4 2022.
• A 5-year average of -$1.2 million and a median of -$39000.0 in 2025 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow jumped 1643.77% in 2023 and tumbled 174.57% in 2025, its largest moves.
• Tracing BNGO's Net Cash Flow over 5 years: stood at -$22.8 million in 2022, then rose by 26.77% to -$16.7 million in 2023, then soared by 102.3% to $383000.0 in 2024, then surged by 286.95% to $1.5 million in 2025, then slumped by 72.06% to $414000.0 in 2026.
• Business Quant data shows BNGO's Net Cash Flow at $414000.0 in Q1 2026, $1.5 million in Q4 2025, and -$512000.0 in Q3 2025.